Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT01748643 Completed - Obesity Clinical Trials

CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity

CURES
Start date: April 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate if a deep neuromuscular block with a continuous infusion of rocuronium titrated to a post-tetanic count (PTC) of 1-2 responses combined with reversal of neuromuscular blockade with sugammadex results in improved surgical conditions for the surgeon and/or improved post-operative respiratory function for the patients as compared to a standard technique with an intubation dose of rocuronium and top-ups as needed to maintain a neuromuscular blockade with a TOF count of 1-2 and reversal of neuromuscular blockade with neostigmine/glycopyrrolate. Furthermore, we want to investigate the effect of pneumoperitoneum, and NMB with rocuronium and reversal with sugammadex or neostigmine/glycopyrolate on cerebral tissue oxygenation.

NCT ID: NCT01746303 Completed - Mood Disorders Clinical Trials

Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline

Start date: January 2010
Phase: N/A
Study type: Interventional

The aim of this study is to determine the efficacy of 6 months' dietary supplementation with omega-3 fatty acids and whole freeze dried blueberry powder in improving cognition in older adults. The effects of each of these interventions alone will also be assessed in order to determine whether the combined treatment confers synergistic or additive benefit relative to the effect of each therapy.

NCT ID: NCT01745497 Completed - Clinical trials for Autism Spectrum Disorder

Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder

Start date: December 2012
Phase: Phase 2
Study type: Interventional

Autism Spectrum Disorders (ASD) are characterized by difficulties in language, social communication, and repetitive and restricted behaviors. ASD affects as many as 1 in 90-150 children. Sleep issues/insomnia is very common in children with ASD (50-80%). Insomnia has a negative impact on both the developmental and behavioral function of the child and the quality of life for the family. Causes of insomnia in children with ASD are multifactorial and can be difficult to treat effectively. Low iron stores, as manifest by low serum ferritin levels, is also common in children with ASD. Both insomnia and low iron stores are associated with Restless Legs Syndrome (RLS) and Periodic Limb Movement of Sleep (PLMS). Children with ASD often have difficulty communicating symptoms or tolerating Polysomnography (Sleep Study). This makes establishing a diagnosis of RLS or PLMS very difficult in children with ASD.

NCT ID: NCT01742832 Completed - Clinical trials for Major Depressive Disorder

Double-Blind Treatment of Major Depressive Disorder With Vilazodone

Start date: May 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of vilazodone for the treatment of major depressive disorder versus citalopram. Doctors want to determine if vilazodone is effective for the treatment of major depressive disorder in those who have not responded to generic selective serotonin reuptake inhibitors (SSRI), which is a class of anti-depressant drugs such as Prozac, Lexapro, Paxil, or Zoloft. Both vilazodone and citalopram have been approved for the treatment of major depressive disorder. This research is being done because the researchers want to find out if vilazodone works in reducing the symptoms of depression significantly more than a generic SSRI.

NCT ID: NCT01739127 Completed - Bipolar Disorder Clinical Trials

Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI

CALM
Start date: November 2012
Phase: N/A
Study type: Observational

The purpose of this study is to compare abdominal weight gain and fat distribution in people taking aripiprazole versus risperidone or quetiapine, to people not taking any of these antipsychotic medications.

NCT ID: NCT01737268 Completed - Bipolar Disorder Clinical Trials

Long-term Study of FK949E in Elderly Bipolar Disorder Patients

Start date: October 29, 2012
Phase: Phase 3
Study type: Interventional

FK949E was administered to elderly bipolar disorder patients with major depressive episode for 52 weeks. Its safety, efficacy, and plasma concentration change were evaluated in an open-label manner.

NCT ID: NCT01737164 Completed - Clinical trials for Glucose Metabolism Disorders

Effect of Age on Glucose and Lipid Metabolism

Start date: September 2010
Phase: N/A
Study type: Interventional

Aging is a major risk factor for the development of type 2 diabetes (T2DM). Approximately 50% of subjects aged ≥65 have diabetes or impaired glucose tolerance, a pre-diabetic state. Purpose: In the proposed study, the investigators will test the hypotheses that the decrease in fat oxidation that occurs in muscle from older human subjects is secondary to an age-mediated reduction in AMPK signaling, in vivo, and that upregulating AMPK signaling through exercise training will result in (and correlate with) increased fat oxidation, reduced intramyocellular lipids, and improved insulin action.

NCT ID: NCT01736631 Completed - Bipolar Disorder Clinical Trials

Cognitive Behavioural Therapy for Social Phobia in People With Bipolar Disorder

Start date: March 2013
Phase: N/A
Study type: Interventional

We are doing this study to find out how well cognitive behavioural therapy for social phobia works in people with bipolar disorder, who also have social phobia.

NCT ID: NCT01731171 Completed - Bipolar Disorder Clinical Trials

Probiotics to Prevent Relapse After Hospitalization for Mania

Start date: November 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if taking a probiotic supplement versus a placebo will lower rates of relapse and improve the clinical course among participants who have been hospitalized for mania. Relapse and clinical course are measured by time to re-hospitalizations, new mood episodes, and changes in mood-related symptoms.

NCT ID: NCT01731119 Completed - Schizophrenia Clinical Trials

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

Start date: December 2012
Phase: Phase 2
Study type: Interventional

The overarching purpose of this pilot study is to collect preliminary data regarding the variability of weight gain associated with lurasidone (Latuda©) treatment of antipsychotic naive children and adolescents in order to inform decisions about including a lurasidone arm in a future large scale trial of different approaches to minimize antipsychotic associated weight gain in the pediatric population. In adults, lurasidone appears to cause minimal weight gain. The participants will be 6-19 years old with psychotic spectrum, mood spectrum, or autism spectrum disorders. They will have 4 weeks or less of lifetime antipsychotic exposure.